Psyence Biomedical expands with Texas ibogaine unit

Psyence Biomedical's strategic move into Texas

On September 23, 2026, Psyence Biomedical Ltd. announced the launch of the Texas Ibogaine Research Corporation, a new entity aimed at coordinating regulatory, clinical, and development activities for its U.S. ibogaine program. This initiative seeks to capitalize on Texas's growing support for ibogaine research, leveraging the state's existing legal and financial frameworks, according to the company's announcement.

Investment in PsyLabs

Psyence Biomedical has committed up to $5 million to Psyence Labs Ltd. to advance scientific research and enhance the production of pharmaceutical-grade ibogaine. Of this investment, $2.4 million has already been secured through PsyLabs' current financing round. The companies have also agreed to a share-for-share exchange valued at approximately $9 million, which will increase mutual ownership and align their clinical and manufacturing efforts.

Company profile and market position

Psyence Biomedical Ltd., listed on Nasdaq, focuses on developing therapeutics based on non-synthetic psilocybin and ibogaine. Through its Texas-based subsidiary, the company aims to address unmet mental health needs with pharmaceutical-grade drug candidates. As of the latest data, the company has an average trading volume of 86,554 and a market capitalization of $24.87 million.

Why it matters

The establishment of the Texas Ibogaine Research Corporation and the significant investment in PsyLabs underscore Psyence Biomedical's commitment to advancing ibogaine research and production. This move could enhance the company's ability to develop treatments for mental health disorders, potentially positioning it as a leader in the emerging field of ibogaine therapeutics.

Psyence Biomedical's strategic investments and partnerships reflect a broader trend of increasing interest in psychedelic compounds for therapeutic use.